Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Archives of Medicine and Health SciencesOpen Access

From Chromatin to Clinic: BET Bromodomain Inhibitors as Novel Disease-modifying Therapies in Heart Failure

View Full Paper
Ask AI
Bookmark
Share

Authors

OEOmar Elsaka

Discussion

Loading...

Member takes

Overview

Investigates BET bromodomain inhibitors for heart failure, suggesting their promise as innovative treatments.

Key Points

  • To explore BET bromodomain inhibitors as disease-modifying therapies in heart failure by analyzing their mechanisms and clinical development.
  • Review of preclinical models and clinical trials involving BET bromodomain inhibitors in heart failure.
  • Examination of molecular pathways affected by BET bromodomain inhibitors.
  • Assessment of safety profiles and toxicity issues related to treatment.
  • BET bromodomain inhibitors improved heart function and reduced fibrosis in preclinical models.
  • Challenges include toxicity and determining optimal dosage for effective treatment.
  • Further research is needed to mitigate adverse effects and understand therapeutic mechanisms.

Cite This Study

Omar Elsaka (2026) studied this question.

synapsesocial.com/papers/6a362fbcdb0793dc1a537253https://doi.org/10.4103/amhs.amhs_179_25
View Full Paper
Ask AI
Bookmark
Share